Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11064545rdf:typepubmed:Citationlld:pubmed
pubmed-article:11064545lifeskim:mentionsumls-concept:C0010055lld:lifeskim
pubmed-article:11064545lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:11064545pubmed:issue1lld:pubmed
pubmed-article:11064545pubmed:dateCreated2000-11-13lld:pubmed
pubmed-article:11064545pubmed:abstractTextThe patient population undergoing repeat coronary revascularization is increasing, with estimates of approximately 15% of these patients in need of alternative conduits. Pre-existing conditions may limit the availability of suitable autogenous vessels for complete coronary revascularization. As an alternative, previous investigators have attempted to develop prosthetic conduits for coronary artery bypass grafting (CABG), but as yet without clinical success. To be of clinical benefit, a prosthetic graft would require demonstrated patency at least as good as a marginal quality autogenous vessel used in the same position, without unexpected adverse effects. The use of a prosthetic graft may also reduce surgical complications associated with conduit harvesting and thereby enhance the speed of patient recovery.lld:pubmed
pubmed-article:11064545pubmed:languageenglld:pubmed
pubmed-article:11064545pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11064545pubmed:citationSubsetIMlld:pubmed
pubmed-article:11064545pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11064545pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11064545pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11064545pubmed:statusMEDLINElld:pubmed
pubmed-article:11064545pubmed:issn1098-3511lld:pubmed
pubmed-article:11064545pubmed:authorpubmed-author:FarrarD JDJlld:pubmed
pubmed-article:11064545pubmed:issnTypePrintlld:pubmed
pubmed-article:11064545pubmed:volume3lld:pubmed
pubmed-article:11064545pubmed:ownerNLMlld:pubmed
pubmed-article:11064545pubmed:authorsCompleteYlld:pubmed
pubmed-article:11064545pubmed:pagination36-40lld:pubmed
pubmed-article:11064545pubmed:dateRevised2009-2-7lld:pubmed
pubmed-article:11064545pubmed:meshHeadingpubmed-meshheading:11064545...lld:pubmed
pubmed-article:11064545pubmed:meshHeadingpubmed-meshheading:11064545...lld:pubmed
pubmed-article:11064545pubmed:meshHeadingpubmed-meshheading:11064545...lld:pubmed
pubmed-article:11064545pubmed:meshHeadingpubmed-meshheading:11064545...lld:pubmed
pubmed-article:11064545pubmed:meshHeadingpubmed-meshheading:11064545...lld:pubmed
pubmed-article:11064545pubmed:meshHeadingpubmed-meshheading:11064545...lld:pubmed
pubmed-article:11064545pubmed:meshHeadingpubmed-meshheading:11064545...lld:pubmed
pubmed-article:11064545pubmed:year2000lld:pubmed
pubmed-article:11064545pubmed:articleTitleDevelopment of a prosthetic coronary artery bypass graft.lld:pubmed
pubmed-article:11064545pubmed:affiliationThoratec Laboratories Corporation, Pleasanton, CA 94588, USA. djfarrar@thoratec.comlld:pubmed
pubmed-article:11064545pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11064545pubmed:publicationTypeReviewlld:pubmed
pubmed-article:11064545pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed